02.02.2014 Views

Evaluation of Speciation Technology - OECD Nuclear Energy Agency

Evaluation of Speciation Technology - OECD Nuclear Energy Agency

Evaluation of Speciation Technology - OECD Nuclear Energy Agency

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

5LI-(Me-3,2-HOPO (X=CH2<br />

5LIO-(Me-3,2-HOPO) (X=O)<br />

3,4,3-LI-(1,2-HOPO)<br />

H(2,2)-(Me-3,2-HOPO)<br />

O NH<br />

OH<br />

N O<br />

CH 3<br />

X<br />

HN O<br />

HO<br />

O N<br />

CH 3<br />

HN N N NH<br />

O<br />

O<br />

O<br />

O<br />

HO N HO N HO N HO N<br />

O<br />

O<br />

O<br />

O<br />

N N<br />

O NH O NH<br />

HN O HN O<br />

HO<br />

OH HO OH<br />

O N N O O N N O<br />

CH 3 CH 3 CH 3 CH 3<br />

The X-ray structures <strong>of</strong> Ce(5LI-(Me-3,2-HOPO))2 (from organic solvent) and Ce(5LIO-(Me-3,2-<br />

HOPO))2 (from water) have been determined. In each case, the central Ce(IV) is eight co-ordinated<br />

from two tetradentate ligands [2a]. The co-ordination polyhedra <strong>of</strong> the two complexes are essentially<br />

square antiprisms. Solution thermodynamic studies gave overall formation constants (log β2) for<br />

Ce(5LI-(Me-3,2-HOPO))2 and Ce(5LIO-(Me-3,2-HOPO))2 <strong>of</strong> 41.9 and 41.6 respectively. From these<br />

constants, extraordinarily high pM values for Ce(IV) are obtained with the two ligands (37.5 and<br />

37.0 respectively). The constants for Pu(IV) are expected to be essentially the same.<br />

The great affinity <strong>of</strong> the tetradentate Me-3,2-HOPO ligands for Pu(IV) under physiological<br />

conditions has been demonstrated in animals [2b,3b]. In mice, 5LI- or 5LIO-(Me-3,2-HOPO) ligand<br />

(30 µmol/kg) injected intraperitoneally 1 hr after intravenous injection <strong>of</strong> 238 Pu(IV)) removed about<br />

82-84% <strong>of</strong> injected Pu(IV) from mice, a much better result than was obtained with an equimolar<br />

amount <strong>of</strong> CaNa3DTPA (67%). It is notable that, unlike the catecholamide ligands, the tetradentate<br />

(Me-3,2-HOPO) ligands injected at the standard dosage promote as much Pu(IV) excretion as the<br />

octadentate ligands 3,4,3-LI-(1,2-HOPO)(86%) or H(2,2)-(Me-3,2-HOPO) (81%). Apparently, the<br />

ligand concentration established in the tissues at the standard injected dosage are large enough to<br />

allow the tetradentate ligands to complex Pu(IV) in competition with biological ligands. However,<br />

octadentate ligands have a 1:1 stoichiometry when binding Pu(IV), and when these are given at a low<br />

dosage or orally, their potency for reducing Pu(IV) in animal tissues exceeds that <strong>of</strong> tetradentate or<br />

hexadentate HOPO ligands. For example, for the octadentate ligand 3,4,3-1,2-HOPO, the same degree<br />

<strong>of</strong> efficacy is observed at injected dosages as low as 0.3 µmol/kg, and it is orally active. All <strong>of</strong> the<br />

tetradentate ligands need larger dosages (at least 10 times) and are not as orally active. Figure 1 shows<br />

the efficacy <strong>of</strong> multidentate ligands (30 µmol/kg) for removing 238 Pu(IV) from mice intraperitoneally<br />

or orally.<br />

Figure 1(a). Removal <strong>of</strong><br />

Pu(IV) by injected ligands<br />

Figure 1(b). Removal <strong>of</strong><br />

Pu(IV) by ingested ligands<br />

3,4,3-LI-(1,2HOPO)<br />

H(2,2)-(Me-3,2-HOPO)<br />

5LIO-(Me-3,2-HOPO)<br />

Skeleton<br />

Live r<br />

S<strong>of</strong>t tissue<br />

Kidneys<br />

3,4,3-LI-(1,2-HOPO)<br />

H(2,2)-(Me-3,2HOPO)<br />

5LIO-(Me-3,2-HOPO)<br />

Skel eton<br />

Liver<br />

S<strong>of</strong>t ti ssue<br />

K idneys<br />

5LI-(Me-3, 2HOPO)<br />

5LI-(Me-3,2-HOPO)<br />

CaNa3DTPA<br />

CaNa3DTPA<br />

Control<br />

Control<br />

0 20 40 60 80 100<br />

0 20 40 60 80 100<br />

Percent <strong>of</strong> Pu Retained at 24 h<br />

Percent <strong>of</strong> Pu Retained at 24 h<br />

A new octadentate, mixed HOPO, ligand was designed and synthesised recently: 3,4,3-LI-(1,2-<br />

Me-3,2-HOPO) [3]. It shows highest ability for removing Pu(IV) at physiological pH, compared with<br />

octadentate 3,4,3-LI-(1,2-HOPO) or H(2,2)-(Me-3,2-HOPO), at injected dosages <strong>of</strong> 0.01 to 0.3 µmol/kg<br />

and when the ligands are given orally. The effectiveness <strong>of</strong> this mixed ligand is remarkable when it is<br />

250

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!